Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVEMIR PENFILL vs LEVEMIR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Insulin detemir is a long-acting insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake in peripheral tissues (muscle, adipose) and inhibit hepatic glucose production. The addition of a fatty acid chain (myristic acid) to the lysine at position B29 allows reversible binding to albumin, prolonging its duration of action.
Insulin detemir is a long-acting basal insulin analogue. It binds to insulin receptors, activating downstream signaling pathways that promote glucose uptake in muscle and adipose tissue, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis. The myristic acid side chain enables reversible binding to albumin, resulting in slow and predictable absorption with a prolonged duration of action.
Glycemic control in patients with diabetes mellitus (FDA approved for type 1 and type 2 diabetes),Off-label: Use in gestational diabetes with insulin
Improving glycemic control in adults and pediatric patients with diabetes mellitus (FDA-approved),Off-label: Use in gestational diabetes, hyperglycemia in hospitalized patients
Subcutaneous injection, starting dose 0.2–0.3 units/kg once daily, titrated to target glucose. Type 1 diabetes: typically 0.3–0.5 units/kg/day. Type 2 diabetes: 10 units once daily, adjusted based on blood glucose.
Subcutaneous injection: 0.2 units/kg once daily or twice daily; usual total daily dose 0.5-1.0 units/kg. Adjust based on blood glucose levels.
Terminal half-life: approximately 13-14 hours (range 12-18 hours) after subcutaneous administration in patients with type 1 diabetes, reflecting prolonged absorption from the injection site. The long half-life supports once-daily dosing.
Terminal elimination half-life: 13–18 hours (up to 24 hours with large doses); reflects prolonged absorption from subcutaneous depot due to dihexyl-deamination modification.
Degraded by general protein catabolism. No specific CYP450 metabolism; cleared via receptor-mediated endocytosis and subsequent intracellular degradation into inactive metabolites.
Insulin detemir is extensively bound to albumin (98-99%). Hepatic metabolism is not significant; it is degraded by proteolytic enzymes into inactive metabolites.
Renal: negligible; metabolized by proteolytic degradation, primarily in the liver and kidneys; <1% excreted unchanged in urine. Fecal: minor.
Renal: minimal, as insulin is extensively reabsorbed and degraded in the proximal tubule; hepatic metabolism: via receptor-mediated endocytosis and degradation by insulin-degrading enzyme; biliary/fecal: negligible.
>98% bound to albumin; binding is reversible and concentration-dependent.
Bound to albumin (>98%); also binds to insulin receptors.
Approximately 0.1 L/kg (range 0.05-0.2 L/kg), indicating distribution primarily into extracellular fluid; Vd is relatively small due to albumin binding.
0.26–0.57 L/kg; reflects distribution primarily into extracellular fluid and tissues with high insulin receptor density.
Subcutaneous: approximately 60-80% after injection; bioavailability is nearly complete compared to other insulin analogs, but may be slightly lower due to local degradation.
Subcutaneous: approximately 85–90%.
GFR <30 m L/min: reduce dose by 25–50% due to reduced insulin clearance; monitor glucose closely. GFR 30-60 m L/min: no formal adjustment but cautious titration. Not studied in dialysis.
No specific dose adjustment recommended based on GFR; monitor glucose closely in renal impairment due to increased risk of hypoglycemia.
Child-Pugh Class B or C: reduce dose by 25–50% due to decreased gluconeogenesis; monitor for hypoglycemia. No specific data for Class A.
No specific Child-Pugh based dose adjustments; monitor glucose closely in hepatic impairment due to altered glucose metabolism.
Weight-based: 0.2–0.5 units/kg/day subcutaneously, typically once daily. Titrate by 2–4 units based on fasting glucose. Not approved for children <6 years.
Children ≥2 years: 0.2-0.5 units/kg subcutaneously once daily or twice daily; titrate based on glucose monitoring.
Initiate at lower doses (e.g., 5–10 units once daily) due to renal impairment, polypharmacy, and increased hypoglycemia risk. Titrate slowly, monitor glucose frequently.
Initiate at lower doses (e.g., 0.1-0.2 units/kg once daily) to minimize hypoglycemia risk; titrate cautiously.
Not indicated for treatment of diabetic ketoacidosis; do not use during episodes of hypoglycemia. Accidental mix-ups with other insulins (e.g., insulin degludec, insulin glargine) have caused severe hypoglycemia.
Never share a Levemir Flex Pen, Pen Fill cartridge, or vial between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
Hypoglycemia (most common adverse reaction; may be severe and life-threatening),Do not dilute or mix with other insulins in the same syringe,Thiazolidinediones (TZDs) coadministration may increase risk of fluid retention and heart failure,Renal or hepatic impairment may increase hypoglycemic risk; dose adjustment may be needed,Not recommended for insulin pump use
Monitor for hypoglycemia, which may be severe and life-threatening,Accidental mix-ups between insulin products can occur; verify label before administration,Changes in insulin regimen should be made cautiously and under medical supervision,Patients with renal or hepatic impairment may be at higher risk for hypoglycemia,May cause fluid retention and worsening of heart failure when used with thiazolidinediones,Hypersensitivity reactions including anaphylaxis, rash, and urticaria may occur,Hypoglycemia and hypokalemia are potential adverse effects
Hypersensitivity to insulin detemir or any excipients,During episodes of hypoglycemia
Hypoglycemia (during episodes),Hypersensitivity to insulin detemir or any of its excipients
No specific food interactions. However, timing of meals should be consistent with insulin action. Carbohydrate intake must be balanced with insulin dose to prevent hyperglycemia or hypoglycemia. Alcohol may potentiate hypoglycemic effect; limit intake and monitor glucose.
No specific food interactions, but timing of meals should be consistent to align with insulin action. Avoid large fluctuations in carbohydrate intake without dose adjustment. Alcohol may increase risk of hypoglycemia.
Insulin detemir (Levemir Penfill) does not cross the placenta in significant amounts. No increased risk of major congenital anomalies has been observed in humans. Poorly controlled diabetes increases risk for fetal malformations and neonatal complications. Strict glycemic control is recommended before conception and throughout pregnancy.
Insulin detemir (LEVEMIR) does not cross the placenta in significant amounts; no teratogenic effects in animal studies. In humans, poor glycemic control is associated with fetal risks, but insulin detemir itself is not considered teratogenic. Risk of maternal hypoglycemia and fetal harm if dosing is poorly managed.
Insulin detemir is a large protein molecule and is not expected to transfer into breast milk in clinically relevant amounts. M/P ratio not established; endogenous insulin is present in breast milk. Considered compatible with breastfeeding; monitor infant for hypoglycemia if large doses are used.
Insulin detemir is a large protein molecule and is not expected to transfer into breast milk in significant amounts. No specific M/P ratio available. It is considered compatible with breastfeeding; monitor infant for signs of hypoglycemia.
Pregnancy induces insulin resistance, especially in second and third trimesters; dose requirements typically increase (may double or more). Postpartum dose reduction is often needed due to sudden drop in insulin resistance. Individualized titration based on frequent blood glucose monitoring.
Insulin requirements typically increase during pregnancy, especially in the second and third trimesters. Dose adjustments may be needed; start with frequent glucose monitoring and titrate doses accordingly. Postpartum, reduce dose to prepregnancy levels.
Insulin detemir (LEVEMIR PENFILL) is a long-acting basal insulin analogue with a duration of action up to 24 hours, but may require twice-daily dosing in some patients. It has a unique mechanism of albumin binding, resulting in less variable absorption and a flatter pharmacokinetic profile compared to NPH insulin. Do not mix with other insulins in the same syringe. Onset is gradual (3-4 hours), peakless, and duration dose-dependent. Use cautiously in renal or hepatic impairment; dose adjustments may be needed.
Levemir (insulin detemir) is a long-acting basal insulin analogue with a flat action profile lasting up to 24 hours. It has a lower risk of hypoglycemia compared to NPH insulin. Dose adjustments are needed in renal or hepatic impairment. Do not mix with other insulins in the same syringe. Onset is slower than glargine; administer once or twice daily at the same time each day.
Inject subcutaneously once or twice daily at the same time each day.,Rotate injection sites (abdomen, thigh, upper arm) to prevent lipodystrophy.,Do not mix with other insulins in the same syringe.,Monitor blood glucose regularly, especially when starting, changing dose, or during illness.,Store unopened pens in refrigerator (2-8°C); opened pens can be kept at room temperature (below 30°C) for up to 28 days.,Avoid alcohol consumption which can increase risk of hypoglycemia.,Recognize symptoms of hypoglycemia (sweating, dizziness, confusion) and hyperglycemia (thirst, frequent urination, blurred vision).,Do not share pens with others, even if needle changed.
Inject subcutaneously into abdomen, thigh, or upper arm; rotate sites within the same region.,Never mix Levemir with other insulins in the same syringe.,Do not use if solution appears cloudy or thickened; it should be clear and colorless.,Store unused vials/penfills in refrigerator (2-8°C); in-use pens can be kept at room temperature below 30°C for up to 42 days.,Monitor blood glucose regularly and watch for signs of hypo- or hyperglycemia.,Do not change insulin type or dose without consulting your healthcare provider.,Discard needles after each use; never share pens or needles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVEMIR PENFILL vs LEVEMIR, answered by our medical review team.
LEVEMIR PENFILL is a Antidiabetic (Long-Acting Insulin) that works by Insulin detemir is a long-acting insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake in peripheral tissues (muscle, adipose) and inhibit hepatic glucose production. The addition of a fatty acid chain (myristic acid) to the lysine at position B29 allows reversible binding to albumin, prolonging its duration of action.. LEVEMIR is a Antidiabetic (Long-Acting Insulin) that works by Insulin detemir is a long-acting basal insulin analogue. It binds to insulin receptors, activating downstream signaling pathways that promote glucose uptake in muscle and adipose tissue, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis. The myristic acid side chain enables reversible binding to albumin, resulting in slow and predictable absorption with a prolonged duration of action.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVEMIR PENFILL and LEVEMIR depend on the specific clinical indication. These are both Antidiabetic (Long-Acting Insulin) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVEMIR PENFILL is: Subcutaneous injection, starting dose 0.2–0.3 units/kg once daily, titrated to target glucose. Type 1 diabetes: typically 0.3–0.5 units/kg/day. Type 2 diabetes: 10 units once daily, adjusted based on blood glucose.. The standard adult dose of LEVEMIR is: Subcutaneous injection: 0.2 units/kg once daily or twice daily; usual total daily dose 0.5-1.0 units/kg. Adjust based on blood glucose levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVEMIR PENFILL and LEVEMIR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVEMIR PENFILL is classified as Category C. Insulin detemir (Levemir Penfill) does not cross the placenta in significant amounts. No increased risk of major congenital anomalies has been observed in humans. Poorly controlled. LEVEMIR is classified as Category C. Insulin detemir (LEVEMIR) does not cross the placenta in significant amounts; no teratogenic effects in animal studies. In humans, poor glycemic control is associated with fetal ri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.